Align Technology Inc. Securities Lawsuit Investigation

Shamis & Gentile P.A., a law firm that advocates for investors who are victims of securities fraud, is investigating potential claims against Align Technology Inc. (NASDAQ: ALGN).

If you purchased or held Align Technology securities and suffered losses, you may be eligible to join this securities investigation and seek compensation.

About Align Technology

Align Technology is a global medical device company best known for its Invisalign clear aligner system, which is used in orthodontics to straighten teeth. The company also develops and markets 3D digital scanners and software for dental practitioners.

The company generates the majority of its revenue from its clear aligner business, which accounts for over 80% of total sales.

The Allegations

The investigation centers on whether Align Technology and its senior executives allegedly misled investors about the company’s financial health and growth prospects between April 30, 2025 and July 30, 2025. During this period, Align Technology issued optimistic guidance and public statements that seemingly overstated demand and growth, while allegedly omitting key information about weakening market conditions.

On April 30, 2025, Align Technology released its first quarter results and provided upbeat guidance for the second quarter, projecting revenue of $1.05–$1.07 billion and promising mid-single-digit year-over-year growth in clear aligner case volumes. The company also predicted full-year 2025 revenue growth of 3.5–5.5% and improving operating margins. CEO Joseph Hogan stated, “Fiscal 2025 is off to a good start,” expressing confidence in the company’s growth across segments. These statements appeared to reassure investors and led to a positive reaction in the stock price, which rose approximately 10% after hours.

However, it is alleged that at the time these statements were made, Align Technology was already aware, or should have been aware, of significant headwinds in its core markets. North American and European clinics were experiencing patient hesitancy, lower case starts, and other demand challenges, including tariff uncertainty and financing issues. Despite this, the company did not disclose these adverse trends, which rendered its guidance and public statements potentially misleading.

The truth began to emerge on July 30, 2025, when Align Technology announced its second quarter results after market close. The company reported Q2 revenue of $1.012 billion, which fell short of both its own guidance and analyst expectations. Clear aligner shipments grew only 0.3% sequentially, far below the “mid-single-digit” growth previously touted. Additionally, Align Technology slashed its Q3 guidance to $965 million from $985 million and cut its full-year clear aligner volume growth outlook to “low-single digits.” The company also announced plans to take $150–$170 million in one-time restructuring and write-down charges in the second half of 2025.

These revelations sharply contradicted the company’s earlier optimistic outlook. The market reacted swiftly and severely: Align Technology’s stock price dropped approximately 33.4% in after-hours trading, falling to $136.14 per share. This represented a loss of about $50–$70 per share from pre-release levels near $190, and wiped out an estimated $4–$5 billion in market capitalization.

Your Rights and Next Steps

This is an active investigation into potential securities law violations by Align Technology and its senior executives. Investors who purchased or held Align Technology securities between April 30, 2025 and July 30, 2025 and suffered financial losses may have legal rights and options. If the investigation uncovers evidence of securities fraud, it may lead to a class action lawsuit seeking recovery for affected investors.

Investors are encouraged to gather documentation of their Align Technology transactions during the class period, including purchase and sale records, account statements and any relevant communications. By participating in the investigation, investors may help strengthen the case and increase the likelihood of a successful recovery if a class action is filed.

Lawyers are ready to help investors understand their rights and guide them through the process. There is no cost or obligation to participate in the investigation at this stage.

You May Be Entitled to Compensation

Securities investigations are time sensitive. If you purchased or held Align Technology securities and suffered losses between April 30, 2025 and July 30, 2025, you may be eligible to join any potential class action and seek compensation for your losses.

To protect your rights and participate in the investigation, complete the form below.